Imaging Utilization for the Staging of Clinically Localized Prostate Cancer

[摘要] For prostate cancer staging, the National Comprehensive Cancer Network currently recommends computed tomography (CT) or magnetic resonance imaging (MRI) for patients with clinical stage ≥T3 disease or clinical stage T1–2 disease with a nomogram probability of lymph node involvement > 20%.1 Bone scan is recommended for a prostate-specific antigen (PSA) > 20 ng/mL (clinical stage T1) or PSA > 10 ng/mL (clinical stage T2), a Gleason score ≥ 8, and clinical stage ≥ T3 or symptoms.

[学科分类] 基础医学